IGFBP-3, insulin-like growth factor binding protein-3; EGFR, epidermal growth factor receptor; ER, estrogen receptor; SphK, sphingosine kinase; S1P, sphingosine 1-phosphate; TNBC, triple-negative breast cancer. 
INTRODUCTION.
Approximately 15% of breast tumors are classified as "triple-negative" breast cancers (TNBC), a term that denotes their lack of ER and PR, and non-amplification of the human EGF receptor 2 (HER2). These tumors, which are particularly aggressive and tend to occur with higher frequency in young women, cannot be targeted by therapies that depend on the expression of functional ER, PR and HER2. Expression of type 1 epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that transduces potent proliferative and cell survival signals in many malignancies including breast cancer (1, 2) , is typically upregulated in TNBC (3), but clinical trials have not shown significant benefit from single-line targeting of EGFR in TNBC (4).
Insulin-like growth factor binding protein-3 (IGFBP-3) is one of six proteins that bind the growth factors IGF-I and -II with high affinity, and modulate their potent proliferative and cellsurvival effects mediated by the type 1 IGF receptor (IGF1R). IGFBP-3 also exerts growthinhibitory activity independent of modulating IGF1R activation by IGFs, and in some tissues this results in suppression of tumor growth and metastasis (5, 6) . By contrast, studies from a number of groups have demonstrated growth-promoting activity of IGFBP-3 in vitro (7) (8) (9) (10) (11) and elevated gene expression of IGFBP3 occurs in a range of malignancies (12) (13) (14) . In human breast tumors, expression of IGFBP-3 is correlated with markers of poor prognosis such as estrogen receptor (ER) and progesterone receptor (PR) negativity, S-phase fraction and tumor size (15) (16) (17) (18) . These clinical observations were recapitulated in a xenograft tumor model in which T47D cells expressing IGFBP-3 as a result of cDNA transfection developed larger tumors than control cells in nude mice (19).
Several mechanisms underlying stimulation of breast cancer cell growth by IGFBP-3 have been described by our laboratory, including the prevention of inhibitory nuclear receptor signaling (20) and the promotion of cell survival by autophagy (21) . Our studies have also revealed that in MCF-10A mammary epithelial cells IGFBP-3 potentiates ligand-stimulated 4 activation of EGFR (11, 22) . The effects of IGFBP-3 on EGFR activation required sphingosine kinase-1 (SphK1), which catalyzes conversion of sphingosine to sphingosine 1-phosphate (S1P), and were mimicked by exogenous S1P, suggesting that S1P mediates potentiation of the EGFR signaling pathway by IGFBP-3 in breast epithelial cells. These findings imply that functional blockade of sphingosine kinase pathway signaling has the potential to block IGFBP-3 stimulatory bioactivity.
Breast cancer cell lines that exhibit molecular features of TNBC, such as the Hs578T and MDA-MB-231 cell lines, reflect the clinical disease with high expression of EGFR and IGFBP-3 (23, 24) . In view of this, we have investigated the role of IGFBP-3 and SphK1 in EGFR signaling in TNBC cells, and the potential efficacy of co-targeting the IGFBP-3/sphingosine kinase and EGFR pathways as a novel therapy for the treatment of these cancers. 
Materials.
Tissue culture reagents and plasticware were from Trace Biosciences (North Ryde, New South Wales, Australia) and Nunc (Roskilde, Denmark). Bovine insulin, EGF, hydrocortisone and α-tubulin antibody were purchased from Sigma. Antibodies against phospho-Tyr1068 EGFR and total EGFR, phospho-Ser473 AKT and total AKT, and phospho-Thr202/Tyr204 ERK1/2 and total ERK1/2 were purchased from Cell Signaling (Beverley, MA) and their specificity verified previously (22) . SphK1 antibody (ab16491) was from Abcam (Walnut, CA), ERα antibody was from Epitomics (Burlingame, CA) and aquaporin 1 (AQP1) was from Santa Cruz.
Recombinant human IGFBP-3 was expressed in human 911 retinoblastoma cells using an adenoviral expression system and purified as previously described (25) . Sphingosine kinase inhibitor 2-(p-hydroxyanilino)-4-(p-chlorophenyl)thiazole (SKi-II) (26) was from Calbiochem.
Gefitinib was purchased from LC Laboratories (Woburn, MA). Electrophoresis and ECL reagents were purchased from Bio-Rad (Hercules, CA), Amrad-Pharmacia (Ryde, New South Wales, Australia) and Pierce (Rockford, IL).
Cell Culture.
The following breast cancer cell lines were purchased from the American Type Culture cultures for use in experiments were established from these stocks every 2-3 months. All lines were maintained in RPMI 1640 medium containing 5% FBS and 10 μg/mL bovine insulin in a humidified 5% CO 2 atmosphere at 37°C, and were negative for mycoplasma contamination.
siRNA-mediated protein knockdown.
Knockdown of protein expression was achieved by electroporation using the following siRNA duplexes from Qiagen (Doncaster, Victoria, Australia): SphK1, Hs_SPHK1_6 and Hs_SPHK1_7; IGFBP-3, Hs_IGFBP3_8 and Hs_IGFBP3_3. To achieve protein silencing, cells were harvested by trypsinization and resuspended at 2.5 x 10 6 cells in 100 μl Amaxa transfection reagent (Lonza Australia Pty Ltd, Mt Waverley, Victoria), then mixed with 1.5 μg silencing siRNA or AllStars negative control siRNA (Qiagen). Nucleoporation was carried out using an Amaxa electroporation unit (Lonza), and cells were transferred to complete medium then plated for specific endpoints as indicated below. Knockdown of protein expression was confirmed by qRT-PCR, in-house IGFBP-3 radioimmunoassay (24) and Western analysis.
Quantitative Real Time-PCR (qRT-PCR).
IGFBP3 and expression was monitored by qRT-PCR using TaqMan Gene Expression Assays (Applied Biosystems, Foster City, CA). Total RNA was isolated from breast cancer cells using TRIzol reagent (Life Technologies Australia) and reverse-transcribed using Superscript III First Strand Synthesis SuperMix (Invitrogen) according to manufacturer's protocols. TaqMan assays for IGFBP-3 (Hs00181211_m1) and SphK1 (Hs00184211_m1) were performed using a Rotor-Gene 3000 thermal cycler (Corbett Research, Mortlake, New South Wales, Australia), with hydroxymethylbilane synthase (HMBS, Hs00609297_m1) amplification used as internal control. Results were analyzed using the Rotor-Gene 6 software.
EGFR activation assays.
Cells were plated into 12 well plates at 2.5 x10 5 cells/well, and maintained in growth medium for 48 h, then medium without insulin for 24 h. Fresh medium containing IGFBP-3 with or without inhibitors was added for 16 h, then EGF was added directly to cells to give final concentrations as indicated for individual experiments. Incubations were continued at 37°C for 10 min, then cells were washed with ice-cold PBS and lysed directly into Laemmli sample 7 buffer (62.5 mM Tris-HCl pH 6.8, containing 20 g/liter SDS, 100 mL/liter glycerol, 1 g/liter bromphenol blue and 50 mM dithiothreitol) at 4°C for 10 minutes. Lysates were transferred to ice-cold Eppendorf tubes, and stored at -80°C until Western analysis.
Plasma membrane isolation.
Fractions containing plasma membranes were isolated to monitor redistribution of SphK1 in response to treatment with IGFBP-3. Briefly, treated cells were washed 2-3 times with cold phosphate buffered saline (PBS), and then harvested in homogenization buffer (20 mM HEPES pH 7.6 containing 250 mM sucrose, 2 mM DTT, 2 mM EDTA, 2 mM EGTA and protease inhibitor cocktail (Roche)). Cells were homogenized in a teflon-glass homogenizer using 50-60 strokes then incubated on ice for 20 min. Cellular debris, and other organelles and nuclei were pelleted by centrifugation at 10,000 x g at 4°C for 20 min, and the supernatant containing cytosolic and membrane fractions was then centrifuged at 100,000 x g for 1 h. The final membrane pellet was resuspended in RIPA lysis buffer (50 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM EDTA) containing 0.1% Triton X-100 and stored at -80°C until Western analysis.
Western blotting.
Cell lysates were prepared for SDS-PAGE analysis by sonication for 15 sec on ice, heating at 95°C for 8 min, and centrifugation for 1 min at 12,000 rpm. Samples were fractionated through 7.5% SDS polyacrylamide gels, then proteins were transferred to Hybond C nitrocellulose proteins were analyzed on replicate blots, and filters were re-probed with α-tubulin antibody as a loading control. Bands were visualized using a FUJIFILM Luminescent Image Analyzer LAS-300 (Stamford, CT), and quantified using Image Guage software (Science Lab 2004).
Cell proliferation assays.
Real-time assessment of cell proliferation over 4-6 days was carried out using the IncuCyte imaging system (Essen Biosciences, Ann Arbor, MI SKi-II (50 mg/kg) or combined SKi-II and gefitinib at these doses, in a volume of 50 μL.
Treatment and tumor measurements were continued until the volume of tumors in control (vehicle) mice was 400-500 mm 3 . Animals were euthanized, and tumors removed, weighed and snap-frozen in liquid nitrogen. Tumors were processed for Western analysis by homogenization in lysis buffer (10 mM Tris, pH 8.0 containing 137 mM NaCl, 10 g/L Triton X-100, 10 % glycerol, and protease and phosphatase inhibitors) using 10 strokes of a teflonglass homogenizer. Samples were sonicated and centrifuged, and the supernatant transferred to fresh tubes for storage at -80°C. Protein was quantified, and 200 μg loaded onto replicate gels for immunoblot analysis of total and phosphorylated EGFR, AKT and ERK1/2 as described above.
Statistical analysis.
All in vitro experiments were performed a minimum of three times, and are shown as Silencing of IGFBP-3 in mammary epithelial cells reduces the ability of EGF to stimulate EGFR phosphorylation, indicating an influence of endogenous IGFBP-3 on receptor activation in these cells (22) . To investigate whether endogenous IGFBP-3 is also required for optimal EGFR activation in breast cancer cells that highly express the protein, IGFBP-3 was silenced using either of two siRNAs, and EGFR phosphorylation was determined after stimulation with EGF. RIA and Western blot of conditioned medium and cell lysates confirmed >90% knockdown of IGFBP-3 protein expression in each cell line (data not shown). As shown in Figure 2C , the ability of EGF to stimulate EGFR phosphorylation was significantly reduced in all cell lines when IGFBP-3 was silenced compared with non-silencing control. We also found that basal EGFR phosphorylation in MDA-MB-468 was reduced in IGFBP-3 knockdown cells in the absence of exogenous EGF ( Figure 2C ). Thus the sensitivity of EGFR to stimulation by EGF in these TNBC cell lines is enhanced by endogenous IGFBP-3.
SphK1 inactivation or silencing blocks IGFBP-3 potentiation of EGFR activation in

TNBC cell lines.
To demonstrate that SphK1 is involved in the effect of IGFBP-3 on EGFR activation in TNBC cells, downregulation of its expression and activity was achieved by siRNA-mediated silencing and pharmacological inhibition, respectively. As shown in Figure 3A , transfection with an siRNA construct targeting SphK1, which reduced its mRNA and protein levels by 75-90% (shown in Figure 1C Figure S3B) .
To study the effects of the EGFR kinase and SphK1 inhibitors in greater detail, real-time proliferation experiments were conducted using low gefitinib and SKi-II doses, selected according to the relative sensitivity of the individual cell lines to these agents determined using the CyQuant assay. Cells were sparsely plated in 96-well plates, changed to medium containing inhibitors 16 h later, and proliferation over the following 72-140 h was imaged using an IncuCyte apparatus. As shown in Figure 5A , at the low doses chosen gefitinib had no significant inhibitory effect when used alone in any TNBC cell line. SKi-II significantly inhibited growth of MDA-MB-231 (from 76 h onwards) and MDA-MB-436 (at the latest time point, 128 h). Remarkably in view of these modest effects when the inhibitors were used separately, the combination of gefitinib and SKi-II virtually abolished cell proliferation in all cell lines, with a significant effect compared with control apparent from 28 h for Hs578T, 52 h for MDA-MB-468, 56 h for MDA-MB-231 and 68 h for MDA-MB-436 (P<0.01).
In view of the profound combined effect of gefitinib and SKi-II on the proliferation of TNBC cells, we investigated the effects of these agents on EGF-stimulated activation of EGFR, and two key survival and proliferative signaling pathways, AKT and ERK1/2. As shown in Figure   5B , EGFR phosphorylation at Y1068 was markedly increased by exogenous EGF in MDA- Figure   5A , cannot be explained by effects on these signaling intermediates. 
The combination of gefitinib and SKi-II inhibits growth of MDA-MB-468 xenograft tumors.
The profound combined effect of EGFR and SphK1 on inhibition of TNBC cells in vitro
DISCUSSION.
This study sought to investigate the potential efficacy of co-targeting growth-stimulatory signaling pathways of two proteins that are highly expressed in TNBC: EGFR and IGFBP-3.
Since many such cancers express EGFR highly (3, 31, 32) , there has been a major interest in drugs that target this pathway, for use either as a single agent or in combination with conventional chemotherapy. In general, EGFR inhibition as a monotherapy for TNBC has been disappointing (33, 34) 
SphK1 mediates these effects of IGFBP-3 in TNBC cells, because when SphK1 expression was silenced using siRNA, IGFBP-3 no longer potentiated EGF-stimulated EGFR phosphorylation. A role for SphK2 in the effects of IGFBP-3 on EGFR signaling seems unlikely, as siRNA-mediated silencing of SphK2 did not prevent IGFBP-3 potentiating EGFR activation in phenotypically normal breast epithelial cells (22) .
Exogenous IGFBP-3 upregulates both SphK1 expression and activity in breast epithelial cells (22) , but here we found no clear correlation between IGFBP-3 expression and either the total amount of SphK1 or the isoforms expressed in breast cancer cells. This suggests that endogenous IGFBP-3 is not a dominant regulator of SphK1 expression in breast cancer cells and that its effects on EGFR signaling relate to its modulation of SphK1 activity rather than expression. Supporting this, exogenous IGFBP-3 increased SphK1 in the membrane fractions of TNBC cells, demonstrating that in these cells IGFBP-3 increases the activity of SphK1.
Translocation of SphK1 to the plasma membrane is a process clearly linked with the generation of sphingosine 1-phosphate (S1P) (37) . While formation of S1P in response to IGFBP-3 was not explicitly shown in the present study, we and others have previously shown induction of SphK activity and increased S1P levels in response to IGFBP-3 in breast and other cell types (22, 38, 39) . The mechanism by which it does so remains unknown. (27, 41, 42) , this was reversed by the proteasome inhibitor MG132, implying their degradation via ubiquitin-proteasomal pathways. MG132 also increased various SphK1 forms to levels above those in untreated cells, suggesting proteasome regulation of the enzyme under basal conditions. The functional consequence of SphK1 degradation in TNBC cells is not clear, but SKi-II-induced degradation of SphK1 has been reported to increase apoptosis of androgensensitive prostate cancer cells (27) perhaps by shifting the sphingolipid rheostat towards the accumulation of pro-apoptotic precursors of S1P, such as sphingosine and ceramide (43) .
Notably, IGFBP-3 has been shown to enhance the apoptotic effects of C2 ceramide in breast cancer cells (44) , suggesting that there may be increased apoptotic activity in breast cancer cells where there is accumulation of ceramide if those cells also express IGFBP-3. We showed previously that functional blockade of EGFR restored sensitivity to growth-inhibitory effects of ectopically-expressed IGFBP-3 in ER+ve breast cancer cells (19), which would be another reason to target the SphK1 pathway rather than IGFBP-3 itself in TNBC where IGFBP-3 is highly expressed.
Although the sensitivity of the four TNBC cell lines to gefitinib and SKi-II was variable, the combination of gefitinib and SKi-II almost completely blocked proliferation of all lines when the two inhibitors were used at concentrations that alone had little or no inhibitory effect.
Importantly, when the combination of SKi-II and gefitinib was tested in an MDA-MB-468 xenograft tumor model, it significantly inhibited tumor growth under conditions where neither gefitinib or SKi-II alone had a significant effect. The mechanisms underlying these combined effects are still to be identified, with no apparent involvement of the key growth-regulatory ERK1/2 or AKT pathways either in vitro or in vivo. 
